TCW Group’s Standard BioTools LAB Stock Holding History

TCW Group’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-89,444	Closed	-$1.96M	–	766
2013 Q3	$1.96M	Sell	89,444 -122,359	-58%	-$2.4M	0.01%	666
2013 Q2	$3.7M	Buy	+211,803	New	+$3.72M	0.02%	530

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCW Group's LAB Position: Q4 2013 in Review

TCW Group sold out of Standard BioTools (LAB) in Q4 2013, closing a stake of 89,444 shares — an estimated $1.96M sold.

TCW Group first reported a position in LAB in Q2 2013 and held it in 2 quarters. The position peaked at $3.7M in Q2 2013. 100 funds tracked by Wall St. Rank hold LAB as of Q4 2013.

TCW Group reported no remaining Standard BioTools position as of Q4 2013 after selling out during the quarter.
TCW Group sold 89,444 Standard BioTools shares in Q4 2013, an estimated $1.96M.
TCW Group first reported a position in Standard BioTools in Q2 2013 and held it in 2 quarters.
TCW Group's Standard BioTools position peaked at $3.7M in Q2 2013.
100 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2013.

Based on TCW Group's 13F filing for Q4 2013, filed 14 Feb 2014.